Cardioprotective Effects of Melatonin in Patients With Cardiomyopathy

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Cardiomyopathies

In brief

The aim of current study is to: Evaluate the cardioprotective effects of melatonin in patients with cardiomyopathy.

Key facts

Study ID

NCT06846086

Run by

Tanta University

People needed

46

Starts

2025-02-20

Expected to finish

2026-02-01

Last updated by the study team

2025-03-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Adult patients (≥18 years) with a confirmed diagnosis of cardiomyopathy based on clinical, echocardiographic, or imaging findings. .
• Stable condition on standard cardiomyopathy medications (e.g., ACE inhibitors, beta-blockers).
• Ability to provide informed consent.

You may not qualify if…

• Recent hospitalization for cardiomyopathy exacerbation (within the last 3 months).
• Severe kidney or liver impairment.
• Use of other investigational drugs or antioxidants.
• Pregnancy or planning to be pregnant in the next 6 months
• Previous known hypersensitivity to melatonin.
• Presence of atrial fibrillation or other significant arrhythmias at baseline.
• Participation in another research.

Where it is running

• Mansoura University Hospital — Dakahlia, Egypt, Mansoura, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.